Status:
COMPLETED
Evaluation of Relapse Presence in Multiple Sclerosis
Lead Sponsor:
Marmara University
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis Relapse
Eligibility:
All Genders
18-85 years
Brief Summary
Purpose: This study aims to investigate the demonstrability of increased inflammation and neurodegeneration in multiple sclerosis (MS) patients in relapse period compared to MS patients in remission b...
Eligibility Criteria
Inclusion
- Patients for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse
- Patients who were followed up with the diagnosis of RRMS
- Healthy controls
Exclusion
- Being younger than 18 years old
- Having any other neurological or metabolic diseases
- Ophthalmological diseases
- A history of optic neuritis and trigeminal symptoms
- Ocular trauma or surgery
- Contact lens use
- The patients who had a relapse attack 6 months prior to the study
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT05218317
Start Date
January 1 2021
End Date
January 1 2022
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marmara University
Istanbul, Turkey (Türkiye), 34899